 |
PRESS
RELEASES 
|
Ad-hoc release; Berlin, September 24th, 2007
MOLOGEN AG: Patent for MIDGE-based vaccine against Leishmaniasis will be granted The Berlin-based biotechnology company MOLOGEN AG announced today that the European Patent Office intends to grant the patent for DNA-vaccines against Leishmaniasis for use in humans and in companion animals. The vaccines contain different combinations of MIDGE-Th1 vectors. Each vector encodes a different target structure (antigen) of the pathogens causing the infection. One of these combinations of antigens is already contained in the MIDGE-based DNA vaccine against Leishmaniasis in companion animals. The vaccine is currently subject of an advanced clinical development program, which is conducted by an undisclosed world-wide leading animal health company.
In 2006, MOLOGEN had entered a research and development, collaboration and license agreement with an undisclosed leading MOLOGEN plans to develop MIDGE-based vaccines also for the use in humans. Leishmaniasis is among the key indications of MOLOGEN’s development program.
About MIDGE-Th1 MIDGE-TH1 facilitates the design of highly specific and most efficient DNA vaccines in a way that the so called TH1 pathway of the immune system is triggered to overcome infections. This TH1 pathway is required to fight pathogens which replicate within the cell.
About Leishmaniasis The pathogens causing the disease Leishmaniasis can be transmitted between animals and human beings. With high prevalence, Leishmaniasis occurs in regions of subtropical and Mediterranean climate. Parasites of the genus Leishmania are transmitted by certain sandflies. The World Health Organisation (WHO) has classified the Leishmaniasis as an emerging disease. To develop new and more effective therapeutics and vaccines against Leishmaniasis, a number of multi-national research programs have been launched.
About MOLOGENMOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.
Disclaimer concerning prognosesCertain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.
|
|
